Abstract The hyperactive kinase FLT3-ITD causes acute myeloid leukemia (AML) and is a prognostic biomarker. We synthesized and characterized MA191 as a novel von Hippel-Lindau (VHL) E3 ubiquitin ligase-based proteolysis targeting chimera (PROTAC) for FLT3. MA191 induces apoptosis in cultured and primary AML patient cells harboring FLT3-ITD (IC50=9.6-11 nM; EC50=0.001-0.883 µM).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Daniel Sasca
Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials
|
By Anne Sophie Platzbecker, Katharina Zoldan, Dominic Brauer, Philipp Kiewe, Daniel Sasca, Katja Sockel, Thomas Illmer, Aristoteles Giagounidis, Daniel Nowak, Kathrin Rieger, Friederike Wortmann, Katharina Götze, Martin Schmidt-Hieber, Karin Mayer, Ursula Vehling-Kaiser, Rudolf Weide, Jens Przybilla, Susanne Melzer, Michael Cross, Marie Schneider, Dirk Hasenclever, Klaus H. Metzeler, Uwe Platzbecker, Stefan Mahlmann
|
Nature
Verified
Abstract Dysregulated innate immune signaling promotes inflammatory suppression of hematopoietic stem and progenitor cell function, contributing to ineffective erythropoiesis in myelodysplastic neoplasms (MDS). The phase 2, open-label CANFIRE and LUCAS trials aimed to determine the efficacy and safety of canakinumab or emavusertib, respectively, in patients with lower-risk MDS (LR-MDS) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN).
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
1 HISTONE METHYLTRANSFERASES AND EPIGENETIC GENE REGULATION Histone methylation is crucial in the precise temporal and spatial coordination of DNA-templated processes.1 The histone methylation landscape is maintained by a diverse group of enzymes catalyzing the addition of methyl groups most commonly to lysine or arginine residues at histone tails.
Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma | Leukemia
Abstract Recent exome-wide studies discovered frequent somatic mutations in the epigenetic modifier ZNF217 in primary mediastinal B cell lymphoma (PMBCL) and related disorders. As functional consequences of ZNF217 alterations remain unknown, we comprehensively evaluated their impact in PMBCL. Targeted sequencing identified genetic lesions affecting ZNF217 in 33% of 157 PMBCL patients.
Pandemic Spread of COVID-19 Mutant Variants Will Facilitate Next-generation Sequencing Capacities for Personalised Medicine in Urologic Oncology
New contagious mutant variants of the SARS-CoV-2 virus have caused coronavirus disease (COVID-19) outbreaks in several countries worldwide and thus changed the face of the pandemic. To combat this public health emergency, the World Health Organization (WHO) Emergency Committee recommended that states should increase worldwide capacities for SARS-CoV-2 genetic sequencing to enhance global understanding of the ongoing virus evolution [ [1] ]. ].
NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML
Daniel Sasca, Jakub Szybinski, Andrea Schüler, Viral Shah, Jan Heidelberger, Patricia S. Haehnel, Anna Dolnik, Oliver Kriege, Eva-Marie Fehr, Wolf H. Gebhardt, George Reid, Claudia Scholl, Matthias Theobald, Lars Bullinger, Petra Beli and Thomas Kindler Blood 2019 133:2305-2319; doi: https://doi.org/10.1182/blood-2018-12-889725 Key Points Aberrant NCAM1 expression confers drug resistance in AML.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Daniel
Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack